JamesLukeGodwinMD

Oncology • New York, NY

Physician

Join to view full profile

Dr. Godwin is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Godwin's full profile

Already have an account?

Office
505 East 70th Street
Weill Cornell Internal Medicine Associates
New York, NY 10021
Phone+1 212-746-4749

Education & Training

New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2011 - 2014
The Warren Alpert Medical School of Brown UniversityClass of 2011

Certifications & Licensure

PA State Medical License 2014 - 2024
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

153 citations
Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelia...
Jacqueline Vuky, Arjun Vasant Balar, Daniel Castellano, Peter H. O'Donnell, Petros Grivas
Journal of Clinical Oncology. 2020-06-17
94 citations
Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer
James Luke Godwin, Shuchie Jaggi, Imali Sirisena, Pankaj Sharda, Ajay D. Rao
Journal for Immunotherapy of Cancer. 2017-05-16
12 citations
Immune Checkpoint Inhibitor Therapy: What Line of Therapy and How to Choose?
Chethan Ramamurthy, James Luke Godwin, Hossein Borghaei
Current Treatment Options in Oncology. 2017-05-22

Press Mentions

Clinical Challenge: Immunotherapy-Related Diabetes in Cancer PatientsJune 25th, 2021